[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,682,463
  • Shares Outstanding, K 59,472
  • Annual Sales, $ 54,030 K
  • Annual Income, $ -412,780 K
  • EBIT $ -476 M
  • EBITDA $ -478 M
  • 60-Month Beta 0.59
  • Price/Sales 31.69
  • Price/Cash Flow N/A
  • Price/Book 1.54

Options Overview Details

View History
  • Implied Volatility 67.46% (+5.34%)
  • Historical Volatility 54.39%
  • IV Percentile 73%
  • IV Rank 11.72%
  • IV High 254.54% on 11/18/25
  • IV Low 42.64% on 02/18/26
  • Expected Move (DTE 10) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 6
  • Volume Avg (30-Day) 177
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 45,387
  • Open Int (30-Day) 45,948
  • Expected Range 27.25 to 27.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.75
  • Number of Estimates 5
  • High Estimate $-1.55
  • Low Estimate $-2.01
  • Prior Year $-1.93
  • Growth Rate Est. (year over year) +9.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.44 +3.78%
on 06/02/26
30.53 -10.12%
on 05/28/26
-0.35 (-1.26%)
since 05/08/26
3-Month
24.29 +12.97%
on 04/27/26
36.35 -24.51%
on 03/31/26
-0.03 (-0.11%)
since 03/06/26
52-Week
22.24 +23.38%
on 11/19/25
46.00 -40.35%
on 11/18/25
-6.89 (-20.07%)
since 06/06/25

Most Recent Stories

More News
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor Agreement diversifies Agios’ rare hematology portfolio with expansion into immune thrombocytopenia,...

AGIO : 27.44 (-3.00%)
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

Results did not meet predefined threshold to support further development in LR-MDS Tebapivat was well tolerated, with no new safety signals observed CAMBRIDGE, Mass., May 29, 2026 (GLOBE NEWSWIRE)...

AGIO : 27.44 (-3.00%)
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable...

AGIO : 27.44 (-3.00%)
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia Mitapivat is now approved for thalassemia in the U.S.,...

AGIO : 27.44 (-3.00%)
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances

Agios Pharmaceuticals (NASDAQ:AGIO) executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently submitted...

AGIO : 27.44 (-3.00%)
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing...

AGIO : 27.44 (-3.00%)
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during...

AGIO : 27.44 (-3.00%)
Agios Pharmaceuticals: Q1 Earnings Snapshot

Agios Pharmaceuticals: Q1 Earnings Snapshot

AGIO : 27.44 (-3.00%)
Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Mitapivat (PYRUKYND ® and AQVESME™) generated worldwide net revenues of $20.7 million in the first quarter of 2026, compared to $8.7 million in the first quarter of 2025 Strong initial U.S. commercial...

AGIO : 27.44 (-3.00%)
Agios Braces for Another Quarter Where the Pipeline Matters More Than the Numbers

Barchart Research What to Expect from AGIO Earnings AGIO Generated April 28, 2026 Current Price $24.80 EPS Estimate $$-1.81 Consensus Rating Moderate Buy Average Move 2.70% Agios Braces for Another Quarter...

AGIO : 27.44 (-3.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 30.34
2nd Resistance Point 29.86
1st Resistance Point 29.08
Last Price 27.44
1st Support Level 27.82
2nd Support Level 27.34
3rd Support Level 26.56

See More

52-Week High 46.00
Fibonacci 61.8% 36.92
Fibonacci 50% 34.12
Fibonacci 38.2% 31.32
Last Price 27.44
52-Week Low 22.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.